Clinical Study

A Phase III Double-Blind Trial For Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo For Patients With Tumors Harboring The Anaplastic Lymphoma Kinase (Alk) Fusion Protein

Posted Date: Jan 4, 2018

  • Investigator: John Morris
  • Specialties: Thoracic Surgery, Hematology/Oncology, Oncology, Cancer, Lung Cancer, Cancer, Radiation Oncology
  • Type of Study: Drug

The purpose of this research is to compare any good and bad effects of using the study drug, crizotinib after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition of crizotinib may help prevent the cancer from returning, but it could also cause side effects. The study will allow researchers to know whether this different approach is better, the same or worse than the usual approach.


To Be Eligible To Participate, Patients Must Have Alk-Positive Non-Small Cell Lung Cancer Which Has Been Removed By A Surgeon.


Early Stage, Nsclc, Cancer, Non-Small Cell Lung Cancer, E4512

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.